We Have cracked the (RNA) code – CureVac’s Highly Optimized RNA

CureVac’s sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA, including mRNA. By modifying the sequence of these molecules, the stability is improved and mRNAs exhibit enhanced translation levels without changing the amino acid sequence of the corresponding proteins. The medical use of mRNA allows transient protein expression in virtually all cell types. Therefore, it provides a safe and efficient method for enabling the human body to produce its own medicine. CureVac uses only naturally occurring, unmodified nucleotides as building blocks for its RNA-based products.

Thermal stability is one of our core features

In ongoing stability studies, we have shown that our lyophilized RNActive® vaccines are stable even under stress conditions:

  • at 25°C/77°F for at least 18 months
  • at 40°C/104°F for at least 6 months

Our stability tests at 5°C (41°F), 25°C (77°F)/60 % relative humidity (RH) and at 40°C (104°F)/75 % RH meet the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) standards for long-term and accelerated storage testing conditions.

Activity of the product could even be shown under extreme conditions such as 50°C (122 °F) storage for at least three months and at 60°C (140 °F) for at least two months. Stability testing is ongoing and is expected to result in even longer storage periods.

The cold chain is a critical, but vulnerable, component of global vaccine distribution and storage. RNActive® vaccines represent a novel technology for the production of safe, efficacious and cost-effective vaccines that are protected against elevated temperature and humidity, as well as inadvertent freezing. Current efforts in vaccine stability are based on additives to existing vaccines or improvements in storage technology. RNActive® vaccines introduce a technology platform where thermal stability is a core feature of all vaccines developed or adapted to the format, ensuring ease of distribution throughout the globe.